Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 67Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 10Lymphoma 10Recurrence 7Neoplasms, Plasma Cell 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Smoldering Multiple Myeloma 4Neoplasms 3Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hematologic Diseases 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Cyclophosphamide 16fludarabine 9Cytarabine 9venetoclax 8Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6Tacrolimus 5Daunorubicin 5Cyclosporine 5ruxolitinib 4ponatinib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Etoposide 4blinatumomab 3asciminib 3Vincristine 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Dexamethasone 3Azacitidine 3revumenib 2quizartinib 2pegfilgrastim 2nilotinib 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Lenalidomide × 90 days × Clear all
NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡